Adhera Therapeutics, Inc. financial data

Symbol
ATRX on OTC
Location
P.O. Box 2161, Wake Forest, NC
State of incorporation
DE
Fiscal year end
December 31
Former names
Marina Biotech, Inc. (to 10/9/2018), MDRNA, Inc. (to 7/21/2010), NASTECH PHARMACEUTICAL CO INC (to 6/9/2008)
Latest financial report
10-Q - Q3 2023 - Nov 20, 2023

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 0.33 % -80.6%
Debt-to-equity -100 % +1.39%
Return On Equity 19 % +27.3%
Return On Assets -5.81K % -574%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 7.22M shares
Common Stock, Shares, Outstanding 5.17M shares +63.5%
Entity Public Float 3.1M USD +288%
Common Stock, Value, Issued 31K USD +72.3%
Weighted Average Number of Shares Outstanding, Basic 4.3M shares +36.2%
Weighted Average Number of Shares Outstanding, Diluted 4.3M shares +36.2%

Income Statement

Label TTM Value / Value Unit Change %
General and Administrative Expense 1.38M USD +21.2%
Operating Income (Loss) -1.28M USD +12.3%
Nonoperating Income (Expense) -3.21M USD -61.2%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -533K USD -620%
Net Income (Loss) Attributable to Parent -4.49M USD -30.1%
Earnings Per Share, Basic -0.88 USD/shares +88.4%
Earnings Per Share, Diluted -0.83 USD/shares -45.6%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 32K USD -57.9%
Assets, Current 44.1K USD -82.8%
Assets 44.1K USD -82.8%
Accounts Payable, Current 2.35M USD +1.72%
Accrued Liabilities, Current 5.55M USD +37.2%
Contract with Customer, Liability, Current 100K USD
Liabilities, Current 26.4M USD +19.5%
Liabilities 26.4M USD +19.5%
Retained Earnings (Accumulated Deficit) -60M USD -8.33%
Stockholders' Equity Attributable to Parent -26.3M USD -20.7%
Liabilities and Equity 44.1K USD -82.8%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -310K USD -43.5%
Net Cash Provided by (Used in) Financing Activities 347K USD +92.8%
Common Stock, Shares Authorized 180M shares 0%
Common Stock, Shares, Issued 5.17M shares +63.5%
Common Stock, Par or Stated Value Per Share 0.01 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 37K USD
Interest Paid, Excluding Capitalized Interest, Operating Activities 4K USD
Deferred Tax Assets, Valuation Allowance 19M USD +73.7%
Deferred Tax Assets, Gross 19.3M USD +76.4%
Deferred Tax Assets, Operating Loss Carryforwards 7.66M USD -8.86%
Preferred Stock, Shares Authorized 100K shares 0%
Additional Paid in Capital 33.6M USD +0.27%
Deferred Tax Assets, Net of Valuation Allowance 0 USD
Preferred Stock, Par or Stated Value Per Share 0.01 USD/shares 0%